Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) is a clinical-stage pharmaceutical company developing topical drug candidates for urological and oral conditions. Its revenue consists primarily of government grants, totaling $536,000 in FY2024 versus $450,000 in FY2023, as the company has no approved products on the market. Lipella's two lead programs are LP-10, a topical tacrolimus formulation targeting hemorrhagic cystitis (HC), and LP-310, a topical tacrolimus formulation targeting oral lichen planus (OLP). The company operates at a significant loss, with total operating expenses of $5.6 million in FY2024 against that $536,000 in grant revenue, producing a net operating loss of $5.1 million for the year. R&D spending was $3.6 million in FY2024. Lipella is headquartered in Pittsburgh, Pennsylvania. Jonathan Kaufman serves as President and Chief Executive Officer, and Douglas Johnston serves as Chief Financial Officer, both as of March 27, 2025.

Revenue model

Grant revenue is the sole current revenue source, totaling $536,000 in FY2024 (up from $450,000 in FY2023). No product revenue has been generated. Future revenue would depend on regulatory approval and commercialization of LP-10 or LP-310.

Products and services

LP-10: topical tacrolimus formulation in clinical development for hemorrhagic cystitis (HC). LP-310: topical tacrolimus formulation in clinical development for oral lichen planus (OLP). Neither product is approved or commercialized as of the filing date.

Customers and end markets

Target end markets are patients with hemorrhagic cystitis and oral lichen planus in the United States and potentially the EU. Physicians and third-party payors are identified as key adoption decision-makers. No commercial customers exist as of the FY2024 10-K filing.

Value-chain role

Pre-commercial drug developer. Lipella conducts research and clinical development internally, funded by grants and equity financing, with no manufacturing or commercial distribution operations disclosed in the filing.

Geographic exposure

Headquartered in Pittsburgh, Pennsylvania. Clinical and regulatory focus on the United States, with the EU mentioned as a potential future market for LP-10 and LP-310.

Source: SEC 10-K, filed 2025-03-28

Industry: Pharmaceutical Preparations Peers: Aptevo Therapeutics Inc Novelstem International Corp Imunon Inc Bio Green Med Solution Inc Minerva Neurosciences Inc NAVIDEA BIOPHARMACEUTICALS, INC. Oncorus, Inc. ProtoKinetix Inc